| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| PTC Therapeutics Inc. | Unesbulin | Intrinsic pontine glioblastoma | Phase 2/3 | Trial Planned | Oral | Oncology |
| PTC Therapeutics Inc. | Vatiquinone - (MIT-E) | Mitochondrial Epilepsy | Phase 2/3 | Trial Completed | Oral | Neurology |
| PTC Therapeutics Inc. | PTC299 (FITE19) | COVID-19 | Phase 2/3 | Trial Completed | Oral | COVID-19 |
| PTC Therapeutics Inc. | EVRYSDI (risdiplam) - (JEWELFISH) | SMA type 1/2/3 switching | Phase 2 | Trial Completed | Oral | Genetic Disorder |
| PTC Therapeutics Inc. | PTC518 - (PIVOT-HD) | Huntington's disease | Phase 2 | Data Released | Oral | Neurology |
| PTC Therapeutics Inc. | PTC857 - (CardinALS) | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Ongoing | Oral | Neurology |
| Pulmatrix Inc. | Pulmazole (PUR1900) | Allergic bronchopulmonary aspergillosis in patients with asthma. | Phase 2b | Trial Discontinued | Inhalation | Respiratory |
| Pulmatrix Inc. | PUR3100 | Acute migraine | Phase 2 | Trial Discontinued | Inhalation | Neurology |